Oncology News

Oncology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Lamoureux F et al. - As GAGs inhibit OPG 1-401 but not OPG 1-194 binding to TRAIL or to RANKL, they may represent potent regulators of OPG availability and antitumor activity in bone tumor microenvironment.

Related Articles

The role of interferons in the treatment of osteosarcoma
Pediatric Blood & Cancer, 11/12/09    Relevance Score: 88%

Reconstruction Using a Frozen Bone Method for Osteosarcoma of the Talus. A Case Report and Review of the Literature
Anticancer Research, 11/11/09    Relevance Score: 88%

Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumourigenic pathways
British Journal of Cancer, 11/06/09    Relevance Score: 88%

Synchronous and metachronous skeletal osteosarcomas: The Norwegian Radium Hospital experience
Acta Oncologica, 10/26/09    Relevance Score: 88%

Tumoral Calcinosis Mimicking Recurrent Osteosarcoma
Radiology Case Reports, 10/23/09    Relevance Score: 88%


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address